Liver disease accounts for two million deaths annually and is responsible for 4% of all
deaths (1 out of every 25 deaths worldwide); approximately two-thirds of all liver-related …

Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …

Background Combating viral hepatitis is part of the UN Sustainable Development Goals
(SDGs), and WHO has put forth hepatitis B elimination targets in its Global Health Sector …

Background Coinfection with hepatitis D virus (HDV) accelerates the progression of liver
disease associated with chronic hepatitis B. Bulevirtide inhibits the entry of HDV into …

Approximately 5% of individuals infected with hepatitis B virus (HBV) are coinfected with
hepatitis D virus (HDV). Chronic HBV/HDV coinfection is associated with an unfavourable …

Background Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV)
and hepatitis D virus infection. In July, 2020, bulevirtide 2 mg received conditional marketing …

Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, characterised by the
greatest increase in risk of cirrhosis, hepatic decompensation and hepatocellular carcinoma …

The global epidemiology of hepatitis D is changing with the widespread implementation of
vaccination against hepatitis B. In high-income countries that achieved optimal control of …

The global burden of viral hepatitis is substantial; in terms of mortality, hepatitis B virus and
hepatitis C virus infections are on a par with HIV, malaria and tuberculosis, among the top …

Background In 2016, of the estimated 257 million people living with chronic hepatitis B virus
(HBV) infection worldwide, only a small proportion was diagnosed and treated. The …